Sagimet Biosciences Inc.
SGMTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from. The $679.3M market capitalization puts SGMT squarely in small-cap range for its industry. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Market Cap
$679.3M
Beta
3.49
P/E (TTM)
—
P/E (Fwd)
-7.37
EPS (TTM)
$-1.22
EPS (Fwd)
$-1.30
ROE
-24.4%
ROA
-16.4%
Cash
$240.1M
Total Debt
$1.9M
Free CF
-$27.8M
52W Change
4.8%
Annual Financials
Cash vs Debt
Where SGMT stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, SGMT finished 2.69% above its 150-day moving average ($7.81) and 9.86% above its 200-day moving average ($7.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SGMT overbought or oversold?
At the October 19, 2026 close, SGMT's RSI(14) was 29.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $240.1M in cash and $1.9M in debt, SGMT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$27.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -24.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 3.49 means SGMT is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, SGMT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Sagimet Biosciences Inc.'s trajectory.